Study on Quercus ilex and Quercus robur Allergen Extracts for Patients with Oak Pollen Allergy

2 1 1

What is this study about?

This clinical trial is focused on studying allergies related to two types of oak trees: Quercus ilex and Quercus robur. The trial will use allergen extracts from these trees to understand how they affect people with allergies. The main goal is to determine the concentration of these allergen extracts that causes a skin reaction similar in size to the reaction caused by a solution of histamine hydrochloride, a substance known to cause a reaction in the skin.

Participants in the study will undergo a skin-prick test, which involves applying small amounts of the allergen extracts to the skin to see if a reaction occurs. This test will also include a positive control using histamine hydrochloride and a negative control using sodium chloride, which is a simple salt solution. The size of the skin reaction, or papule, will be measured to assess the response to the allergen extracts.

The study aims to better understand the skin reactions caused by these specific tree pollen allergens in individuals with a history of inhalant allergies, such as rhinitis, rhinoconjunctivitis, or asthma, related to Quercus ilex and Quercus robur. This research could help improve allergy testing and treatment for people sensitive to these tree pollens.

1 initial assessment

Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes reviewing the clinical history of inhalant allergy to Quercus ilex and Quercus robur.

A skin prick test is performed to ensure a positive reaction to the allergen extract, with a mean papule diameter of at least 3 mm. Additionally, a test with histamine dihydrochloride at 10 mg/mL is conducted to confirm a mean papule area of at least 7 mm².

2 skin prick test procedure

The skin prick test involves the application of solutions containing allergen extracts from Quercus robur and Quercus ilex, as well as control solutions.

The solutions are applied cutaneously, meaning they are placed on the skin. The test includes a negative control (sodium chloride) and a positive control (histamine hydrochloride).

3 observation and measurement

After the application of the solutions, the size of the skin papule induced by each concentration is measured. This is the primary variable of the study.

The objective is to determine the concentration of allergenic extract that causes a papule size equivalent to that produced by the histamine solution.

4 completion of trial

The trial is expected to conclude by December 30, 2024. Participants will be informed of the results and any relevant findings related to their participation.

Who Can Join the Study?

Have a history of allergy symptoms like sneezing, runny nose, itchy eyes, or breathing problems due to Quercus ilex and Quercus robur.
Show a positive result on a skin test, where a small bump of at least 3 mm appears after exposure to the allergen, or have specific IgE antibodies for the allergen. IgE is a type of protein in the blood that indicates an allergic reaction.
Have a skin reaction with a bump area of at least 7 mm² when tested with a solution of Histamine dichlorohydrate at 10 mg/mL. Histamine dichlorohydrate is a substance used to test for allergies.
Be between 18 and 64 years old.
Both men and women can participate.
Must be able to understand the study and agree to participate by signing a consent form.
Women who can have children must have a negative pregnancy test before joining the study.

Who Cannot Join the Study?

Having an allergy to Quercus ilex or Quercus robur. These are types of oak trees, and an allergy means your body reacts negatively to them.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

No sites found in this category

Trial status

Country	Status	Recruitment Start
Spain	Not recruiting	08.02.2023

Trial locations

Investigated drugs:

Quercus ilex allergen extract is used in this trial to determine its ability to cause an allergic skin reaction. The goal is to find out how much of this extract is needed to produce a skin reaction similar in size to that caused by a standard histamine solution.

Quercus robur allergen extract is also being tested in the trial for its potential to cause an allergic skin reaction. Like the Quercus ilex extract, the aim is to measure the concentration required to create a skin reaction comparable to the one caused by a standard histamine solution.

Allergy to Quercus ilex and Quercus robur – This condition involves an allergic reaction to pollen from the Quercus ilex and Quercus robur trees, commonly known as holm oak and English oak, respectively. When individuals with this allergy are exposed to the pollen, their immune system mistakenly identifies it as harmful, triggering symptoms such as sneezing, runny nose, itchy eyes, and skin reactions. The progression of symptoms can vary depending on the level of exposure and individual sensitivity. In some cases, exposure may lead to more severe reactions, including difficulty breathing or skin rashes. The condition is typically seasonal, coinciding with the pollination period of these trees.

Trial ID:

2024-515189-14-00

Protocol code:

T525-STD-043

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on Quercus ilex and Quercus robur Allergen Extracts for Patients with Oak Pollen Allergy

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?